Jennifer Rosenthal
Corporate Officer/Principal bei VIRALYTICS LTD.
Profil
Jennifer Rosenthal is currently the Director of Quality & Regulatory Affairs at Viralytics Pty Ltd.
and the Director of Quality & Regulatory Affairs at Clarity Pharmaceuticals Ltd.
She previously worked as the Director of Clinical & Regulatory Affairs at The Sustainable Nutrition Group Pty Ltd.
Dr. Rosenthal holds a doctorate degree from Monash University.
Aktive Positionen von Jennifer Rosenthal
| Unternehmen | Position | Beginn |
|---|---|---|
| VIRALYTICS LTD. | Corporate Officer/Principal | - |
| CLARITY PHARMACEUTICALS LTD | General Counsel | 01.10.2019 |
Ehemalige bekannte Positionen von Jennifer Rosenthal
| Unternehmen | Position | Ende |
|---|---|---|
| THE SUSTAINABLE NUTRITION GROUP LTD | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Jennifer Rosenthal
| Monash University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CLARITY PHARMACEUTICALS LTD | Health Technology |
| Private Unternehmen | 2 |
|---|---|
The Sustainable Nutrition Group Pty Ltd.
 The Sustainable Nutrition Group Pty Ltd. Agricultural Commodities/MillingProcess Industries The Sustainable Nutrition Group Ltd. produces, manufactures, and distributes a range of hemp products in Australia. It is involved in hemp seed selection, farming, processing, and packaging, as well as distribution and sale of bulk and retail products. The company's products include hand sanitizers, hemp oils, hemp seeds, hemp protein powders, and hemp flour under the APH and Mt Elephant brands to retail, wholesale, and white label customers. The company was founded by James Hood and Tracie Rams dale in 1995 and is headquartered in Newtown, Australia. | Process Industries |
Viralytics Pty Ltd.
 Viralytics Pty Ltd. BiotechnologyHealth Technology Viralytics Pty Ltd. engages in the development and commercialization of oncolytic immunotherapies that harness the power of certain viruses to infect and kill cancer cells. Its product, CAVATAK, is a genetically unmodified proprietary formulation of the common cold Coxsackievirus Type A21. The company was founded in 1984 and is headquartered in Sydney, Australia. | Health Technology |
